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Objectives
To describe the dynamics of the infusion regimen ‘s
dosage of the Citrate-Calcium, when they are used as
anticoagulants in systems of CRRT and, determine if the
numbers of changes reduce and reach a constant velocity
of infusion as the therapy times progresses, to prove the
utility of dynamic dosage in hemodiafiltration therapy.
Methods
A descriptive and comparative study about a prospective
data basis is made. All the patients with CRRT require-
ments, admitted in ICU from September 2014 to March
2015 are included. Variables as motive of therapy, daily
dosage of the therapy, days of therapy, half-life of systems
on the first three days, global half-life of systems, type of
anticoagulation, daily mean dosage of citrate-calcium,
number of daily changes in these dosages and complica-
tions are analysed. The number of changes of citrate-
calcium and the day of therapy is compared, such as the
filter’s length and the kind of anticoagulation.
Results
A total of 36 patients are obtained, with a therapy’s length
of 331 days, an average of 7.31 days (SD 7.10), a mean
half-life system on the first three days of 2.13 days (SD
0.9), a mean dialysis dosage 1411 ml/h (SD 494.6), an aver-
age filtration dosage 700.9 ml/h (SD 583.1), removal
dosage 99.8 ml/h (SD 71.5). Indication of therapy was
management of volume 61% and filtratrion of Urea and
electrolytes in 33% of the cases. The type of the anticoagu-
lation was Heparine 61% and Citrate-Calcium 25%.
A total of 62 days of anticoguation with citrate is
described, the average of length 6.8 days. Mean Citrate
dosage was 3.02 mmol/l (SD 0.47) and mean calcium
dosage 1.5mmol/l (SD 1.04). No significant bleeding,
severe electrolyte, or calcium disorders were observed.
A progressive decrease of dialysis and convection dosage
is observed along the days of treatment with linear regres-
sion (p < 0.01). Consequently a decrease of 25% of dyalisis
solutions consumption is noticed compared to historical
controls.
Global half-life systems were longer in patients with
Citrate-Calcium regimens, average 67.25 hours (IC 60.33-
74.16) compared to patients with Heparine 54.14 hours IC
(47.47- 60.80) p < 0.05.
Also is described a reduce in the number of changes in
the citrate-calcium dosage along the period of therapy
correlation coefficient (p < 0.05).
Conclusions
A dynamic dose of hemodiafiltration is taken in our ICU
patients with CRRT requirements, consequently a greater
efficiency in therapies is observed. Changes in Citrate-
Calcium dosage descreases along the days and reaches a
constant velociy infusion, so Citrate-Calcium regimens
becomes a safe and easy-managment option for anticoagu-
lation in critical patients.
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